Search

Author/Creator Eoli, M

2. OS05.6.A Modification of the tumor microenvironment in patients with glioblastoma using autologous, genetically modified, hematopoietic stem cell-based therapy: the TEM-GBM STUDY (NCT03866109). (5th September 2022)

Authors:
Finocchiaro, G; Eoli, M; Gentner, B; Bruzzone, M; Di Meco, F; Mortini, P; Olivi, A; Naldini, L; Russo, C; Ciceri, F
Journal:
Neuro-oncology
Issue:
Volume 24(2022)Supplement 2
Page Start:
ii13
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. OS2.3 Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma <GBM> patients <PTS>. (19th September 2018)

Authors:
Lombardi, G; de Salvo, G; Rudà, R; Franceschi, E; Eoli, M; Faedi, M; Pace, A; Lolli, I; Rizzato, S; Germano, D; Pasqualetti, F; Farina, M; Magni, G; Bellu, L; Caccese, M; Pambuku, A; Bergo, E; Indraccolo, S; Gardiman, M; Soffietti, R
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii219
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. OS7.3 Health-related quality of life (HRQoL) evaluation in the REGOMA trial: a randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients. (6th September 2019)

Authors:
Lombardi, G; Del Bianco, P; Brandes, A; Eoli, M; Rudà, R; Ibrahim, T; Lolli, I; Pace, A; Daniele, B; Pasqualetti, F; Rizzato, S; Bergo, E; Caccese, M; Padovan, M; Soffietti, R; De Salvo, G; Zagonel, V
Journal:
Neuro-oncology
Issue:
Volume 21(2019)Supplement 3
Page Start:
iii14
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P01.040 Identification of a predictive biomarker of response to regorafenib in relapsed glioblastoma patients <REGOMA trial>. (19th September 2018)

Authors:
Lombardi, G; Indraccolo, S; de Salvo, G; Verza, M; Magni, G; Eoli, M; Rudà, R; Franceschi, E; Faedi, M; Lolli, I; Rizzato, S; Caccese, M; Gardiman, M; Zagonel, V
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii237
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P01.040 Identification of a predictive biomarker of response to regorafenib in relapsed glioblastoma patients <REGOMA trial>. (19th September 2018)

Authors:
Lombardi, G; Indraccolo, S; de Salvo, G; Verza, M; Magni, G; Eoli, M; Rudà, R; Franceschi, E; Faedi, M; Lolli, I; Rizzato, S; Caccese, M; Gardiman, M; Zagonel, V
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii237
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. P01.052 Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux -M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406). (19th September 2018)

Authors:
van den Bent, M; French, P; Eoli, M; Sepulvado, J; Walenkamp, A; Weller, M; Looman, J; Ansell, P; Gorlia, T; Golfinopoulos, V
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii241
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. P03.04 Observational, prospective study on complications and tolerability of PICC (central venous catheter with peripheral insertion) in neurooncological patients. (19th September 2018)

Authors:
Simonetti, G; Sommariva, A; Basso Ricci, C; Anghileri, E; Botturi, A; Eoli, M; Gaviani, P; Lamperti, E; Moreschi, C; Silvani, A
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii276
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. P05.02 A phase I/IIa dose escalation study evaluating the safety and efficacy of autologous CD34+ enriched hematopoietic progenitor cells genetically modified for human interferon-α2 in patients with GBM and an unmethylated MGMT promoter (TEM-GBM-001). (6th September 2019)

Authors:
Gentner, B; Ciceri, F; DiMeco, F; Legnani, F; Eoli, M; Pollo, B; Farina, F; Mazzoleni, S; Russo, C; Naldini, L; Finocchiaro, G
Journal:
Neuro-oncology
Issue:
Volume 21(2019)Supplement 3
Page Start:
iii34
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗